Literature DB >> 10353182

Immune function in hyperbaric environments, diving, and decompression.

I Brenner1, R J Shephard, P N Shek.   

Abstract

The purpose of this review is to examine the influence of exposure to hyperbaric oxygen (HBO2) deep diving, and decompression on various facets of the immune response. Potential changes during exposure include a decrease in the CD4+:CD8+ ratio, a decreased proliferation of lymphocytes, and an activation of neutrophils with migration to regions of high oxygen pressure. There may also be an activation of the complement cascade during decompression. Clinical indicators of overall immune suppression include a decreased response to antigens, a weakening of autoimmune responses, and a slower rejection of allografts. In professional divers, immune changes are at least partially offset by acclimatization, and seem to have little clinical significance. However, patients receiving HBO2 are a more vulnerable group; in their case, exposure may impair immune surveillance, and a careful monitoring of immune function may be important to the success of treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353182

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  10 in total

1.  Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages.

Authors:  R M Benson; L M Minter; B A Osborne; E V Granowitz
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

2.  Human amniotic fluid mesenchymal stem cells in combination with hyperbaric oxygen augment peripheral nerve regeneration.

Authors:  Hung-Chuan Pan; Chun-Shih Chin; Dar-Yu Yang; Shu-Peng Ho; Chung-Jung Chen; Shiaw-Min Hwang; Ming-Hong Chang; Fu-Chou Cheng
Journal:  Neurochem Res       Date:  2009-01-17       Impact factor: 3.996

Review 3.  Venous gas embolism as a predictive tool for improving CNS decompression safety.

Authors:  A Møllerløkken; S E Gaustad; M B Havnes; C R Gutvik; A Hjelde; U Wisløff; A O Brubakk
Journal:  Eur J Appl Physiol       Date:  2011-05-19       Impact factor: 3.078

4.  Hyperbaric oxygen therapy as a sole agent is not immunosuppressant in a highly immunogenic mouse model.

Authors:  Adam Gassas; Weixian Min; A Wayne Evans; Susan Carter; George K Sándor; Eyal Grunebaum
Journal:  Bone Marrow Res       Date:  2010-08-03

5.  Beluga (Delphinapterus leucas) granulocytes and monocytes display variable responses to in vitro pressure exposures.

Authors:  Laura A Thompson; Tracy A Romano
Journal:  Front Physiol       Date:  2015-05-06       Impact factor: 4.566

Review 6.  Application of hyperbaric oxygen in liver transplantation.

Authors:  Hu Lv; Cui-Hong Han; Xue-Jun Sun; Wen-Wu Liu
Journal:  Med Gas Res       Date:  2016-12-30

7.  Therapeutic effect of hyperbaric oxygen in psoriasis vulgaris: two case reports and a review of the literature.

Authors:  Glenn Butler; Julio Chávarri Michaels; Noori Al-Waili; Michael Finkelstein; Michael Allen; Richard Petrillo; Zev Carrey; Bangaruraju Kolanuvada; Bok Y Lee; Alfonso Gonzales Riera; Cesar Chávarri Michaels; Gary Urteaga
Journal:  J Med Case Rep       Date:  2009-08-10

Review 8.  Nutritional considerations during prolonged exposure to a confined, hyperbaric, hyperoxic environment: recommendations for saturation divers.

Authors:  S K Deb; P A Swinton; E Dolan
Journal:  Extrem Physiol Med       Date:  2016-01-07

9.  Effects of hyperbaric conditions on fecal microbiota.

Authors:  Morihiko Oya; Yutaka Tadano; Yasuhiro Takihata; Wakana Murakami; Shigenori Fujii; Kenji Tamai; Yuji Morimoto; Fumitaka Ikomi; Tetsuji Tokunaga
Journal:  Biosci Microbiota Food Health       Date:  2018-08-30

10.  Laparoscopic Nissen fundoplication: The effects of high-concentration supplemental perioperative oxygen on the inflammatory and immune response: A randomised controlled trial.

Authors:  Mario Schietroma; Sara Colozzi; Beatrice Pessia; Francesco Carlei; Marino Di Furia; Gianfranco Amicucci
Journal:  J Minim Access Surg       Date:  2018 Jul-Sep       Impact factor: 1.407

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.